Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialLancet 2022 Mar 31;[EPub Ahead of Print], JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, V Chiarion-Sileni, L de la Cruz Merino, MA Khattak, D Schadendorf, GV Long, PA Ascierto, M Mandala, F De Galitiis, A Haydon, R Dummer, JJ Grob, C Robert, MS Carlino, P Mohr, A Poklepovic, VK Sondak, RA Scolyer, JM Kirkwood, K Chen, SJ Diede, S Ahsan, N Ibrahim, AMM Eggermont
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.